GHRP-2
Pralmorelin · GHRP2
Growth hormone secretagogue that acts on the ghrelin receptor to amplify GH pulses.
Overview
GHRP-2 (pralmorelin) is a growth hormone secretagogue that acts on the ghrelin (GHS-R1a) receptor to amplify pulsatile growth hormone release. It sits in the same family as GHRP-6 but is generally considered more potent at GH release while producing less of the appetite stimulation that defines GHRP-6, which is why it gets preferred when hunger is an unwanted side effect. Like other GHRPs it works through a pathway distinct from GHRH analogs, so stacking the two produces a stronger combined GH response. The estimated half-life is roughly one hour with around 50% subcutaneous bioavailability, driving multiple daily doses in research contexts. Human pharmacokinetic data is limited and GHRP-2 is not an approved medication.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.0 days
- Bioavailability
- 50%
- Typical dose
- 0.1–0.3 mg
Related compounds
Ipamorelin
Selective GHRP secretagogue releasing growth hormone with relatively minimal cortisol/prolactin effect.
GHRP-6
Ghrelin-receptor secretagogue that increases GH and notably stimulates appetite.
MK-677 (Ibutamoren)
Orally active growth hormone secretagogue (ghrelin receptor agonist) that elevates GH and IGF-1; the non-peptide counterpart to injectable GHRPs.
Comments
Loading comments…